Korea approves LG Chem’s combination drug for diabetes, dyslipidemia
IndustryAug 2, 2017
LG Chem said Wednesday that South Korea’s Ministry of Food and Drug Safety had approved Zemiro, a combination drug that simultaneously treats diabetes and dyslipidemia, a condition in which an abnormal amount of lipids exist in the blood. Developed by LG Chem’s biopharmaceuticals unit, Zemiro is a new combination tablet that merges LG’s diabetes drug Zemiglo -- a Diepeptidyl peptidase-4 inhibitor -- with the lipid reduction drug ingredient rosuvastatin. LG Chem`s production plant in Osong, Nort